INTRODUCTION {#s1}
============

Nasopharyngeal carcinoma (NPC), derived from the nasopharynx, is an epidemic cancer in Southeast Asian countries, Southeast China and North Africa \[[@R1]\]. NPC patients often were diagnosed at advanced stages and radiotherapy (RT) was used to be the recommended option for these patients \[[@R2]\]. However, only 30%-50% NPC patients with RT were able to survive for 5 years \[[@R3]\]. Meanwhile, chemical compounds like SSRP1 that are able to reduce the proliferation of NPC tumor cells was identified in previous studies \[[@R4]\]. As a result, the combination of chemotherapy and RT was hypothesized to be an effective therapy to improve the survival status of NPC patients. And such result was verified by studies in the current literatures \[[@R5]\].

Three primary chemoradiotherapies was introduced to control locoregionally advanced NPC: concurrent chemoradiotherapy, concurrent chemoradiotherapy plus adjuvant chemotherapy and concurrent chemoradiotherapy plus neoadjuvant chemoradiotherapy. It was revealed that the 3 mentioned methods worked in totally different mechanisms and focused on different purposes. For instance, chemoradiotherapy is prepared for the purpose of multiplying the treatment effects and neoadjuvant chemoradiotherapy is able to reduce the size of tumor before the implementation of RT. It was suggested that patients with neoadjuvant chemoradiotherapy exhibited a lower risk of recurrence in comparison to those with the monotherapy of RT \[[@R6]\].

Although some MA was conducted to compare different chemoradiotherapies, most randomized clinical trials (RCTs) can only compare two or three arms of therapies due to resource constraints and ethical issues. As a result, simultaneously comparison to the efficacy of several chemoradiotherapies cannot be achieved by RCTs or conventional meta-analysis. Therefore, the approach of mixed-treatment comparisons or network meta-analysis (NMA) was adopted in this study in order to overcome the above limitations. It was also expected to examine whether combined chemoradiotherapy was able to provide NPC patients with enhanced efficacy from this NMA. For this reason, evidence was synthesized from studies in which adjuvant chemotherapy, concurrent chemoradiotherapy, neoadjuvant chemotherapy or their binary combination therapies (A, C, N, A+C, N+C and A+N) were included and compared.. By conducting such a study, genuine consensus can be reached in the current literature which is critical to patients with NPC.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

As was revealed in the flow chart (Figure [1](#F1){ref-type="fig"}), a total of 781 articles were identified by two reviewers (PubMed: 175, Embase: 598, additional reviews: 17). Then 595 irrelevant articles as accompanied with 102 duplicates were excluded, resulting in 84 articles for full-text assessment. After another 32 articles were removed, 52 publications with a total of 10,081 NPC patients were included in the eligibly study list. The baseline characteristics of included studies were shown in Table [1](#T1){ref-type="table"}. Besides, the network plots revealing the distribution of trials for each outcome were shown in Figure [2](#F2){ref-type="fig"}. The size of nodes was proportional to the number of patients with that comparator and the numbers on the edges between two nodes indicated the number of included direct evidences.

![Flow chart of study selection](oncotarget-08-39782-g001){#F1}

###### Characteristics of studies included in the network meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study              Size   Follow-up\   Disease Stage             Age   Male (%)   Radiotherapy   Chemotherapy                                                                    
                            (month)                                                                                                                                                
  ------------------ ------ ------------ ------------------------- ----- ---------- -------------- -------------- ---------------------------------------------------------------- ---------------------------------------------------
  Al-Sarraf, 1998    193    30           AJCC III--IV,WHO I-III    50    67.0       RT             70             C (cisplatin) + A (fluorouracil, cisplatin)                      Control

  Cao, 2015          180    58.97        AJCC II--III              47    73.0       IMRT           70             C (cisplatin)                                                    Control

  Chan, 1995         82     28.5         WHO III                   44    92.0       RT             58-66          N (fluorouracil, cisplatin)                                      Control

  Chan, 2005         350    66           WHO I-III,UICC II-IV      45    80.0       RT             66             C (cisplatin)                                                    Control

  Chen, 2008         316    29           AJCC III--IVb             46    73.4       RT             70             C (cisplatin) + A (fluorouracil, cisplatin)                      Control

  Chen, 2011         220    60           AJCC II--III,WHO II-III   42    70.7       RT             68-70          C (cisplatin)                                                    Control

  Chen, 2012         508    37.8         WHO III-IVb               44    77.0       RT             66             C (cisplatin) + A (fluorouracil, cisplatin)                      C (cisplatin)

  Chi, 2002          157    49.5         WHO I-III                 46    77.9       RT             70.2           A (leucovorin, fluorouracil, cisplatin)                          Control

  Chua, 1998         334    30           AJCC I--IV,M0             47    75.0       RT             71             N (epirubicin, cisplatin)                                        Control

  Cvitkovic, 1996    339    49           WHO I-III,M0              42    75.0       RT             65-70          N (bleomycin, epirubicin, cisplatin)                             Control

  Ding, 2011         56     3            TNM II-IV                 48    60.7       RT             70             C (cisplatin) + A (fluorouracil, cisplatin)                      C (cisplatin)

  Fountzilas, 2012   141    55           WHO I-III                 49    71.0       RT             70             N (epirubicin, cisplatin, paclitaxel) + C (cisplatin)            C (cisplatin)

  Ge, 2009           52     \-           TNM II-III                54    76.9       RT             70             C (CMNa)                                                         Control

  Guan, 2016         69     35           AJCC I--IV,WHO II-III     48    85.7       IMRT           60             C (cisplatin)                                                    Control

  Hareyama, 2002     80     49           WHO I-III                 50    75.0       RT             66-68          N (fluorouracil, cisplatin)                                      Control

  Huang, 2012        200    \-           WHO II-III                44    56.0       RT             66-78          N (fluorouracil, carboplatin) + C (carboplatin)                  C (carboplatin)

  Huang, 2015        408    133.3        UICC II-IV                45    77.6       RT             66-78          N (floxuridine, carboplatin) + C (carboplatin)                   N (floxuridine, carboplatin)

  Hui, 2009          65     \-           UICC III-IV               50    61.8       RT             78.4           N (docetaxel, cisplatin) + C (cisplatin)                         C (cisplatin)

  Kong, 2015         200    \-           WHO III-IV                50    63.0       RT             66-75          C (fluorouracil)                                                 Control

  Kwong, 2004\*      219    37           AJCC II--IV,WHO I-III     45    69.1       RT             66             C (uracil, tegafur)                                              Control

                                                                                                                  A (fluorouracil, cisplatin, vincristine,\                        C (uracil, tegafur) + A (fluorouracil, cisplatin\
                                                                                                                  bleomycin, methotrexate)                                         , vincristine, bleomycin, methotrexate)

  Lai, 2007          95     \-           TNM I-IV                  51    76.6       RT             70-80          C (CMNa)                                                         Control

  Lee, 2010          348    60           WHO III-Ivb               46    72.0       RT             68             C (cisplatin) + A (fluorouracil, cisplatin)                      Control

  Lee, 2011          441    73.2         WHO III-IVb               46    74.0       RT             66             C (cisplatin) + A (fluorouracil, cisplatin)                      Control

  Liang, 2008        72     \-           TNM I-IV                        62.2       RT             60-70          C (CMNa)                                                         Control

  Liao, 2008         48     \-           TNM II-IV                 51    58.3       RT             68-74          C (CMNa)                                                         Control

  Lin, 2003          284    65           WHO I-III                 45    71.6       RT             70-74          C (fluorouracil, cisplatin)                                      Control

  Liu, 2006          211    52           TNM I-IV                  46    88.5       RT             68-70          C (CMNa)                                                         Control

  Liu, 2010          44     \-           TNM III-IVa               51    72.7       RT             72-74          C (CMNa)                                                         Control

  Ma, 2001           456    62           WHO I-III                 46    69.0       RT             68-72          N (bleomycin, fluorouracil, cisplatin)                           Control

  Ma, 2009           98     24           TNM III-Iva               48    77.6       RT             70             N (fluorouracil, cisplatin, paclitaxel) +\                       C (fluorouracil, cisplatin)
                                                                                                                  C (fluorouracil, cisplatin)                                      

  Rossi, 1988        229    \-           T1-4,N0-3                 49    70.0       RT             60-70          A (vincristine, cyclophosphamide, adriamycin)                    Control

  Ruste, 2011        30     \-           WHO III-IVb               36    62.5       RT             70             C (cisplatin) + A (fluorouracil, cisplatin)                      N (fluorouracil, cisplatin) + C (cisplatin)

  Tan, 2008          60     \-           TNM I-Iva                 51    50.0       RT             68-70          C (CMNa)                                                         Control

  Tan, 2015          172    40.8         WHO II-III                49    82.6       IMRT           70             N (paclitaxel, gemcitabine) + C (cisplatin)                      C (cisplatin)

  Wang, 2010         66     \-           TNM III                   45               RT             70-74          C (CMNa)                                                         Control

  Wang, 2014         695    66.4         WHO I-II                  45    77.7       IMRT           67-76          C (cisplatin)                                                    Control

  Wee, 2015\*\*      83     49.4         WHO I-Iib                 49    68.7       IMRT           67.5           C (cisplatin)                                                    C (cisplatin) + A (fluorouracil, cisplatin)

                                                                                                                  N (docetaxel, fluorouracil, cisplatin or docetaxel, cisplatin\   \-
                                                                                                                  or fluorouracil, cisplatin) + C (cisplatin)                      

  Wen, 2014          60     \-           AJCC III-Ivb              46    57.0       RT             60-66          C (docetaxel)                                                    Control

  Wu, 2006           40     \-           TNM III-IV                56    75.0       RT             70-74          C (CMNa)                                                         Control

  Wu, 2013           115    114          WHO II-III                                 RT             70-74          C (oxaliplatin)                                                  Control

  Wu, 2014           35     31.9         UICC III-Ivb,WHO II-III   36    72.2       RT             70             C (H-R3)                                                         Control

  Xu, 2014           338    60           AJCC III-Ivb              49    74.1       RT             70-76          N (fluorouracil, cisplatin) + A (fluorouracil, cisplatin)        C (fluorouracil, cisplatin) +\
                                                                                                                                                                                   A (fluorouracil, cisplatin)

  Xu, 2015           86     37.4         UICC II-IV                51    72.1       IMRT           66             C (cisplatin)                                                    Control

  Yang, 2007         60     \-           T1-4N0-3M0                41    66.7       RT             60-70          C (CMNa)                                                         Control

  Yang, 2012         60     3            TNM II-IV                 63    73.3       RT             72             C (CMNa)                                                         Control

  Yi, 2014           333    \-           WHO III-IV                47    73.9       IMRT           70-74          C (cisplatin)                                                    Control

  Zeng, 2014         234    22           WHO II-III                48    86.0       RT             70             C (cisplatin)                                                    Control

  Zhang, 2005        115    24           WHO II-III,AJCC III--IV   46    67.8       RT             70-74          C (oxaliplatin)                                                  Control

  Zhang, 2008        100    \-           TNM III-IV                                 RT             68-70          C (CMNa)                                                         Control

  Zhang, 2008        45     \-           TNM III-IV                41    80.0       RT             70-74          C (CMNa)                                                         Control

  Zhang, 2015        799    55.27        WHO I-III                 46    73.0       IMRT           60             N (docetaxel, paclitaxel, cisplatin or docetaxel,\               C (cisplatin)
                                                                                                                  paclitaxel, cisplatin, fluorouracil) + C (cisplatin)             

  Zhou, 2011         60     \-           T2N2M0                    46    80.0       RT             70-74          C (CMNa)                                                         Control
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Kwong, 2004\*, four arms study; Wee, 2015\*\*, three arms study; Abbreviations: AJCC, American Joint Committee on Cancer; WHO, World Health Organization; UICC, International Union Against Cancer; TNM, T, Tumor, N, regional lymph node, M, metastasis; RT, radiotherapy; IMRT, intensity-modulated radiotherapy; A, Adjuvant chemotherapy; C, Concurrent chemotherapy; N, Neoadjuvant chemotherapy; CMNa, sodium glycididazole.

![The network plot of included interventions](oncotarget-08-39782-g002){#F2}

Result of conventional MA {#s2_2}
-------------------------

Direct comparisons from conventional MA were shown in Table [2](#T2){ref-type="table"}. NPC patients with C were associated with significantly decreased HR and increased probability of CR compared with the control group. The above trend was also presented in survival benefit between patients with C+A and those in the control group. Besides, patients with N+C exhibited an average increase of 9% in the 3-year OS (HR = 1.09, 95% CI = 1.01-1.16) in relation to those with C+A

###### Meta-analysis results for pair-wise comparisons

  Intervention 1   Intervention 2   5 years OS          3 years OS          1 years OS           CR
  ---------------- ---------------- ------------------- ------------------- -------------------- -------------------
  **A**            **Control**      1.22 (0.85, 1.75)   1.20 (0.81, 1.80)   1.16 (0.59, 2.28)    1.11 (0.86, 1.43)
  **C**            **Control**      0.68 (0.52, 0.90)   0.66 (0.48, 0.90)   0.32 (0.15, 0.67)    1.16 (1.06, 1.28)
  **C+A**          **Control**      0.65 (0.53, 0.80)   0.62 (0.47, 0.81)   0.46 (0.26, 0.81)    1.23 (0.81, 1.88)
  **N**            **Control**      0.84 (0.69, 1.02)   0.86 (0.69, 1.06)   0.96 (0.63, 1.48)    1.04 (0.89, 1.21)
  **C+A**          **A**            0.74 (0.36, 1.55)   0.69 (0.26, 1.84)   1.47 (0.03, 80.96)   \-
  **C+A**          **C**            0.80 (0.50, 1.29)   0.76 (0.40, 1.45)   1.10 (0.23, 5.20)    1.09 (0.72, 1.66)
  **N+A**          **C+A**          0.84 (0.53, 1.34)   1.06 (0.27, 4.08)   \-                   \-
  **N+C**          **C**            0.94 (0.74, 1.21)   0.82 (0.43, 1.56)   0.59 (0.14, 2.53)    1.04 (0.83, 1.30)
  **N+C**          **C+A**          \-                  1.09 (1.01, 1.16)   0.89 (0.38, 2.05)    \-
  **N+C**          **N**            1.04 (0.63, 1.71)   1.10 (0.54, 2.21)   0.82 (0.15, 4.47)    \-

Abbreviation: A, Adjuvant chemotherapy; C, Concurrent chemotherapy; N, Neoadjuvant chemotherapy

Result of NMA {#s2_3}
-------------

Several trends were revealed by mixed-treatment comparisons, as recorded in Table [3](#T3){ref-type="table"} and shown graphically in [Figure S1 and Figure S2](#SD1){ref-type="supplementary-material"}. In the outcomes of 5-year OS, five therapies were associated with a significantly reduced HR compared with the control group (C: HR = 0.70, 95% CI: 0.59-0.85; C+A: HR = 0.64, 95% CrI: 0.52-0.79; N+C: HR = 0.74, 95% CrI: 0.57-0.96; N: HR = 0.80, 95% CI: 0.65-0.98; N+A: HR = 0.54, 95% CrI: 0.31-0.93). C, C+A and N+A also presented a decreased HR compared with A. With respect to 3-year, the result was similar to that during the five year period versus the control group. Similarity occurred in comparisons with A. Considering 1-year OS, significant result was obtained in the primary comparisons with control group and A, along with wider interval distributions. Additional significant result was achieved when we compared C, C+A and N+C with N (C: HR = 0.44, 95% CrI: 0.21-0.90; C+A: HR = 0.51, 95% CrI: 0.27-0.96; N+C: HR = 0.44, 95% CrI: 0.21-0.94), which may indicate the difference in the short-term performance. According to the result, we found that there was consistency among 1-year, 3-year and 5-year OS status. Furthermore, NPC patients with C, C+A, N+C and N appeared to have significantly higher possibility of CR compared with the control group.

###### Network meta-analysis results for long-term and short-term prognoses

                          3 years OS                                                                                                                                      
  ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ------------------------
  **5 years OS**          **Control**             1.16 (0.79, 1.70)       **0.70 (0.55, 0.90)**   **0.64 (0.52, 0.80)**   **0.80 (0.65, 0.99)**   0.68 (0.17, 2.70)       **0.72 (0.56, 0.91)**
  1.13 (0.79, 1.60)       **A**                   **0.61 (0.39, 0.95)**   **0.56 (0.36, 0.86)**   0.69 (0.45, 1.07)       0.59 (0.14, 2.45)       **0.62 (0.40, 0.96)**   
  **0.70 (0.59, 0.85)**   **0.62 (0.42, 0.93)**   C                       0.92 (0.70, 1.20)       1.14 (0.84, 1.55)       0.97 (0.24, 3.88)       1.02 (0.77, 1.34)       
  **0.64 (0.52, 0.79)**   **0.57 (0.39, 0.83)**   0.91 (0.70, 1.18)       **C+A**                 1.24 (0.95, 1.63)       1.06 (0.27, 4.12)       1.11 (0.95, 1.31)       
  **0.80 (0.65, 0.98)**   0.71 (0.47, 1.06)       1.13 (0.88, 1.45)       1.25 (0.93, 1.67)       **N**                   0.85 (0.21, 3.41)       0.89 (0.68, 1.17)       
  **0.54 (0.31, 0.93)**   **0.48 (0.25, 0.90)**   0.77 (0.44, 1.35)       0.84 (0.51, 1.39)       0.68 (0.38, 1.21)       **N+A**                 1.05 (0.27, 4.15)       
  **0.74 (0.57, 0.96)**   0.65 (0.42, 1.01)       1.05 (0.82, 1.33)       1.15 (0.83, 1.60)       0.92 (0.71, 1.20)       1.36 (0.75, 2.48)       **N+C**                 
                          **CR**                                                                                                                                          
                                                                                                                                                                          
  **1 year OS**           **Control**             1.73 (0.82, 3.78)       **3.06 (2.25, 4.28)**   **2.46 (1.16, 6.40)**   **2.89 (1.09, 8.98)**   \-                      **4.35 (1.89, 11.86)**
  1.12 (0.57, 2.18)       A                       1.76 (0.77, 3.97)       1.41 (0.50, 4.86)       1.68 (0.47, 6.66)       \-                      2.51 (0.83, 8.63)       
  **0.40 (0.21, 0.73)**   **0.35 (0.14, 0.88)**   **C**                   0.81 (0.36, 2.04)       0.95 (0.34, 3.01)       \-                      1.43 (0.64, 3.52)       
  **0.46 (0.28, 0.76)**   **0.42 (0.18, 0.95)**   1.17 (0.59, 2.34)       **C+A**                 1.20 (0.30, 4.28)       \-                      1.79 (0.52, 5.70)       
  0.91 (0.60, 1.37)       0.81 (0.37, 1.78)       **2.29 (1.11, 4.72)**   **1.95 (1.04, 3.65)**   **N**                   \-                      1.51 (0.36, 6.03)       
  \-                      \-                      \-                      \-                      \-                      **N+A**                                         
  **0.40 (0.20, 0.80)**   **0.36 (0.14, 0.93)**   1.01 (0.48, 2.11)       0.86 (0.45, 1.66)       **0.44 (0.21, 0.94)**   \-                      **N+C**                 

Abbreviation: A, Adjuvant chemotherapy; C, Concurrent chemotherapy; N, Neoadjuvant chemotherapy

5 years overall survival, 3 years overall survival, 1 year overall survival, represented by hazard ratio (HR) and 95% credible interval (CrI), and complete response represented by odds ratio (OR) and 95% credible interval (CrI). In lower half of the table, row treatments are compared against column treatments, whereas in the upper half, column treatments are compared against row treatments.

Ranking of SUCRA {#s2_4}
----------------

Firstly, the SUCRA values revealing the rank of abovementioned therapies in different outcomes were recorded in Table [4](#T4){ref-type="table"}. Overall, C together with the combined approaches of C+A and N+C exhibited to be the most competitive therapies with respect to prognostic outcomes and complete response according to the SUCRA values. Another noteworthy therapy was N+A, it was the most efficacy combination in 5y-OS outcomes. Then, the result was well displayed by the cluster analysis in Figure [3](#F3){ref-type="fig"}, in which the included therapies were categorized into different groups based on their SUCRA values. Cluster analysis suggested that the above three chemoradiotherapy appeared to be divided into the most efficacious group located in the upper right corner of the cluster plots. On top of that, the cluster plots showed that the results of included outcomes were substantially similar in this NMA.

###### Surface under the cumulative ranking curve (SUCRA) values of each intervention

  Interventions   5 years OS   3 years OS   1 years OS   CR
  --------------- ------------ ------------ ------------ -------
  **Control**     0.131        0.181        0.191        0.018
  **A**           0.058        0.092        0.144        0.298
  **C**           0.647        0.680        0.832        0.670
  **C+A**         0.792        0.851        0.723        0.512
  **N**           0.423        0.469        0.285        0.622
  **N+A**         0.883        0.597        \-           \-
  **N+C**         0.566        0.631        0.824        0.864

Abbreviation: A, Adjuvant chemotherapy; C, Concurrent chemotherapy; N, Neoadjuvant chemotherapy

![Clustered ranking plot of the network\
The plot is based on cluster analysis of surface under the cumulative ranking curves (SUCRA) values. Each plot shows SUCRA values for two outcomes. Each color represents a group of treatments that belong to the same cluster. Treatments lying in the upper right corner are more effective and safe than the other treatments.](oncotarget-08-39782-g003){#F3}

Consistency between direct and indirect evidence {#s2_5}
------------------------------------------------

Since the consistency model was introduced in the NMA, this assumption was supposed to be evaluated in this NMA. As suggested by the net heat plot in Figure [4](#F4){ref-type="fig"}, no significant inconsistency appeared in the comparison with respect to the survival outcomes. However, substantial inconsistency was observed from the comparison between C and C+A under the endpoint of CR (*P* = 0.041), as was shown in the node splitting plot ([Figure S3](#SD1){ref-type="supplementary-material"}).

![Net heat plot\
Warm color in the net heat plot indicates that significant inconsistency may arise from a specific design or comparison and this trend is illustrated by the intensity of the color.](oncotarget-08-39782-g004){#F4}

DISCUSSION {#s3}
==========

In this study, a comprehensive and quantitative comparison among the existed chemotherapies given as the integral part of radiotherapy in patients with NPC was successfully conducted. This evaluation presented both direct and indirect evidence through pairwise meta-analysis and mixed meta-analysis. The statistical differences presented in the results would lead us to give an appropriate estimate and find out the optimal clinical choices.

As the SUCRA results revealed, therapeutic strategies based on concurrent chemoradiotherapy, including concurrent chemoradiotherapy alone or combined with adjuvant or neoadjuvant chemotherapy, were recommended as the first-line therapies, when the characteristics of individuals are not clarified. It was reported that platinum-based concurrent chemoradiotherapy had been accepted by the National Comprehensive Cancer Network as the standard recommendation for locally advanced NPC since the Intergroup 0099 study was published in 1998 \[[@R7]\]. And its superiority in clinical performance over traditional radiotherapy had been demonstrated in subsequent RCT studies \[[@R8]\] and MAs \[[@R9], [@R10]\]. It was reported that tissue fibrosis and vascular changes of tumor in locally recurrent NPC attributed to its poor sensitivity to radiotherapy \[[@R11]\]. However, chemotherapy was found to be a highly responded therapy instead \[[@R12]\]. Thus concurrent chemotherapy provided a reinforced efficacy by increasing the sensitivity of NPC toward radiotherapy. When comparing the add-on chemotherapies based on concurrent chemoradiotherapy (C+A and N+C), no head-to-head comparison was conducted according to the retrieve results. Besides, no statistically significant result had been pooled, with merely marginal differences. Additionally, the survival benefit in the documented records was as ambiguous as the NMA result, meaning that the addition of adjuvant or neoadjuvant chemotherapy had not been significantly translated to the improvement in overall survival benefit and complete response rate.

Among those chemotherapies binding with conventional radiotherapy, the number of included publications was limited, which meant further evidence was still required to give a more accurate evaluation. Neoadjuvant chemotherapy, followed by radiotherapy alone with adjuvant chemotherapy, is given an appreciable preference, especially in the outcomes of 5-year overall survival rate, although recorded by merely one publication, which is documented as a long-term, updated result reported by *Xu et al* \[[@R13]\]. Undoubtedly, the relevant ranking was lack of solid credibility. However, according to this document, this kind of chemotherapy added to traditional radiotherapy was comparable with concurrent plus adjuvant chemoradiotherapy in the aspect of overall survival benefits, and was considered as a potential alternative to the latter. As a result, this potentially preferable therapy could be a research focus of further RCT studies. The separated neoadjuvant chemotherapy followed by radiotherapy was documented by 5 publications, among which the latest one was updated in 2002 by *Hareyama et al* \[[@R14]\]. It had a middle position in the SUCRA ranking score and presented a moderate performance in the including outcomes. However, its limitation was reported as a low proportion of patient response \[[@R15]\], failure to achieve the primary goal of eradicating distant micro-metastases because of non-sufficient dosage \[[@R16]\] or a failed translation from the reduction in local relapses into an overall survival advantage due to local or regional recurrence \[[@R16]\]. As a result, almost no further researches were reported and neoadjuvant chemotherapy became an integral part of concurrent chemoradiotherapy. Adjuvant chemotherapy plus radiotherapy exhibits to be not advantageous in the case of improving overall survival and tent to result in more complete response than the control group of radiotherapy. The included publication pooled no significant improvement, just consistent with our NMA. It was criticized for the regimen was thought to be suboptimal \[[@R17]\] or dose-intensity was reduced \[[@R17]\]. Despite the low ranking in our NMA result, adjuvant chemotherapy was reported to be efficacious in decreasing the chance of systemic relapse \[[@R18]\]. Consequently, a more reasonable estimate would be given if outcomes were taken into consideration.

Radiotherapy alone seemed to be the last choice for patients with NPC. Although it was considered useful in the early-stage NPC, the low cure rate made it unsatisfying \[[@R19], [@R20]\], which was coincident with the result that we had demonstrated in NMA. Especially in those with locally recurrent NPC, re-irradiation is associated with severe complications at high doses, which could even be the primary cause of death \[[@R21]\]. The confirmed therapeutic advantage of concurrent chemoradiotherapy over radiotherapy was the result of the fact that most included trials were comparing with the conventional technique. However, there had been development in this traditional therapy. Intensity-modulated radiotherapy (IMRT), a modern radiotherapy technique, had been applied in more studies, especially in the recent trials \[[@R22]--[@R24]\]. In this case, the tumor volumes were delineated more accurately, so better dose distribution could be adopted \[[@R22]\]. Thus, significant improvement has been diluted when patients were given the additional chemotherapy. Besides, three-dimensional conformal radiation therapy (3D-CRT) was another developed technique, providing improved calculation, shielding, and the classic field arrangement compared with the traditional 2D technique \[[@R25]\]. The primary purpose of chemotherapy is to increase the disease control locally and distantly \[[@R26], [@R27]\]. And its advantageous clinical performance had been proved in a large quantity of trials. Nevertheless, the tendency had emerged that advanced radiotherapy technology could be alternative to concurrent chemoradiotherapy.

Though successfully conducted, a number of limitations still existed in this NMA. First, the detailed information that was directly related to survival rate, such as distant metastasis, and the toxicity of chemotherapy with the corresponding adverse responses was not included. Though most adverse responses were manageable and uncomplicated, and not associated with death, chemotherapy was still poorly tolerable. Moreover, undoubtedly the addition of chemotherapy was responsible for some severe events. For example, the increase of hematologic events in patient with neoadjuvant or adjuvant chemotherapy had been reported \[[@R23]\]. Second, as we had mentioned above, specific comparison was limited due to the lack of available head-to-head trials, especially among those chemotherapies based on traditional radiotherapy. It was insufficient to pool a clear result and give a critical conclusion. Finally, we did not use the detailed data of individual patients. In fact, the included patients are belonging to different stages of NPC sufferers. And they were characterized by different symptoms, so researchers were tent to divide them into subgroups. It had been proposed that radiotherapy alone can be sufficient treatment for early-stage NPC patients. Combined concurrent chemoradiotherapy with adjuvant chemotherapy was recommended for those at intermediate risk stage. Aggressive neoadjuvant chemotherapy, followed by CCRT and adjuvant chemotherapy may be the choice for high-risk patients \[[@R28]\].

In conclusion, in view of survival rate and complete response, concurrent chemoradiotherapy with adjuvant chemotherapy (C+A), concurrent chemoradiotherapy with neoadjuvant chemotherapy (N+C)and concurrent chemoradiotherapy (C) itself was considered as the first-line treatment according to the NMA result. Even so, it was worth noting that the advanced modern radiotherapy technique had the potential to be an alternative. Cautious and approaches based on evidence should be maintained. Guidance from our NMA was recommended to be integral with individual characteristics.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

Literature search was conducted in electronic databases by two independent reviewers. Multiple resources were searched accordingly for the purpose of preventing selection bias: China National Knowledge Internet (CNKI), PubMed and Embase. Literature search was not restricted to any language or type of publication. The following key terms accompanied with their entry terms were used to build a searching query: "nasopharyngeal neoplasms", "radiotherapy", "chemotherapy", "chemoradiotherapy" and etc. The searching results were updated in September 2016.

Studies were included if they were randomized controlled trials (RCT) which combined at least one chemotherapy regimen with radiotherapy. Besides that, patients in the included studies \[[@R1]--[@R11], [@R13], [@R14], [@R17], [@R24], [@R29]--[@R65]\] were diagnosed with NPC (stage I to IV) according to the criteria set by the American Joint Committee on Cancer (AJCC), the World Health Organization (WHO), the International Union against Cancer (IUAC) and the tumor node metastasis (TNM) staging system.

Data extraction {#s4_2}
---------------

The process of data extraction was accomplished by two independent reviewers. The following study characteristics were included for each research: (1) the basic information of the research, including the first author, published year, the size of samples and the follow-up duration; (2) the patients characteristics, including tumor stage, age and sex; (3) the regimens, including the type and dose of radiotherapy and the interventions for comparison; (4) outcomes, including 1-year, 3-years and 5-years overall survival (OS) and complete response (CR). If the same study had been published for more than once, the one with longer following-up duration would be preferred. risk of bias was also evaluated by using the famous Cochrane risk of bias assessment tool \[[@R54]\]. Each study was classified as having high, low or unclear risk of bias.

Statistical analysis {#s4_3}
--------------------

Since not only the short-term efficacy of chemoradiotherapies but also their long-term efficacy in NPC patients was concerned in this NMA, the 3-year and 5-year OS were selected as major outcomes whereas the 1-year and CR were selected as secondary outcomes. We used the hazard ratio (HR) and its 95% confidence intervals (CIs) to measure the relative efficacy between two comparators when survival data were synthesized from individual studies. A significantly increased HR (HR \> 1) suggested that one therapy may be less efficacious than another and vice versa. Besides, the statistics of odds ratio (OR) and its 95% (CIs) were also computed when CR data were synthesized from individual studies. The random-effects model was introduced for pair-wise meta-analysis, which generated summary statistics for every direct comparison. We used *I****2*** statistics to evaluate the between-study heterogeneity, in which *I****2*** \> 50% was considered high heterogeneity. Then R 3.2.3 and STATA 13.0 were adopted to conduct NMA. Summary statistics and their 95% credible intervals (CrIs) were computed by the approach of NMA. Furthermore, the cumulative ranking probability of each chemoradiotherapy was computed so that chemoradiotherapy can be ranked with respect to each outcome. Additionally, the net heat plot was created by the software to evaluate the consistency between direct and indirect comparison. Warm color in the net heat plot indicates that significant inconsistency may arise from a specific design or comparison and this trend is illustrated by the intensity of the color. Besides, the node splitting method was adopted to test the presence of significant inconsistency for each comparison and *P*-value \< 0.05 concludes the significance of inconsistency. Finally, chemoradiotherapies were categorized into different groups by using the approach of cluster analysis.
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OS

:   overall survival,

CR

:   complete response

NPC

:   nasopharyngeal carcinoma

NMA

:   network meta-analysis

HR

:   hazard ratio

C

:   concurrent chemoradiotherapy

A

:   adjuvant chemotherapy

N

:   neoadjuvant chemotherapy

C+A

:   concurrent chemoradiotherapy with adjuvant chemotherapy

C+N

:   concurrent chemoradiotherapy with neoadjuvant chemotherapy

N+A

:   neoadjuvant chemotherapy with adjuvant chemotherapy

CIs

:   confidence intervals

OR

:   odds ratio

RT

:   radiotherapy

RCTs

:   randomized clinical trials
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:   China National Knowledge Internet

AJCC

:   American Joint Committee on Cancer
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:   World Health Organization

IUAC

:   International Union against Cancer
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